Characterization of filovirus host factors and small-molecule inhibitors of infection

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 473350

Grant search

Key facts

  • Disease

    Ebola
  • start year

    2022
  • Known Financial Commitments (USD)

    $574,965.45
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Côté Marceline
  • Research Location

    Canada
  • Lead Research Institution

    University of Ottawa
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Filoviruses are negative strand RNA viruses that can cause severe hemorrhagic fevers in human following zoonotic spillover events. Outbreaks of filovirus diseases are increasing in frequency and our knowledge of the Filoviridae family expended greatly recently with the discovery of new filoviruses in Europe, Africa and Asia that are also potentially pathogenic. While a vaccine against Ebola virus, one of the 5 species of ebolaviruses, is available, it does not protect well against all ebolaviruses and does not protect against other pathogenic filoviruses. Therefore, pan-filoviral antiviral therapy is urgently needed. In this proposed project, we aim to gain a molecular understanding of the filovirus-host cell interactions with the overarching goal of identifying and characterizing pan-filovirus small molecule inhibitors for the development of new pan-filoviral antiviral therapies.